09:53 AM EST - Med BioGene Inc. : announced the publication in the Journal of Thoracic Oncology of data demonstrating a second, independent validation of the 15-gene signature to be marketed as GeneFx® Lung entitled "Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients." The study validated in a prospective and blinded manner the prognostic accuracy of the GeneFx Lung signature in an independent cohort of 181 early-stage (I and II) non-small-cell lung cancer (NSCLC) tumor specimens in different histologic subtypes. Med BioGene Inc.
shares V.MBI are trading up $0.01 at $0.11.
